Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Monday 17 July, 2017

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 2933L
GlaxoSmithKline PLC
17 July 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

70.538 (personal contribution)

£16.18

174.682 (personal contribution)

£16.18

190.188 (personal contribution)

£16.18

70.538(personal contribution)

£16.18

174.669 (personal contribution)

£16.18

190.176 (personal contribution)

£16.18

70.538 (matching shares)

£16.18

174.682 (matching shares)

£16.18

190.188 (matching shares)

£16.18

70.538 (matching shares)

£16.18

174.669 (matching shares)

£16.18

190.176 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,741.582

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

51.658 (personal contribution)

£16.18

118.682 (personal contribution)

£16.18

99.029 (personal contribution)

£16.18

51.658 (personal contribution)

£16.18

99.017 (personal contribution)

£16.18

51.658 (matching shares)

£16.18

118.682 (matching shares)

£16.18

99.029 (matching shares)

£16.18

51.658 (matching shares)

£16.18

99.017 (matching contribution)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

840.088

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

166.446 (personal contribution)

£16.18

166.433 (personal contribution)

£16.18

166.446 (matching shares)

£16.18

166.433 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

665.758

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

98.527 (personal contribution)

£16.18

230.682 (personal contribution)

£16.18

172.780 personal contribution)

£16.18

98.514 (personal contribution)

£16.18

230.669 (personal contribution)

£16.18

172.780 (personal contribution)

£16.18

98.527 (matching shares)

£16.18

230.682 (matching shares)

£16.18

172.780 (matching shares)

£16.18

98.514 (matching shares)

£16.18

230.669 (matching shares)

£16.18

172.780 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,007.904

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

36.169 (personal contribution)

£16.18

85.292 (personal contribution)

£16.18

62.593 (personal contribution)

£16.18

36.169 (personal contribution)

£16.18

85.292 (personal contribution)

£16.18

62.582 (personal contribution)

£16.18

36.169 (matching shares)

£16.18

85.292 (matching shares)

£16.18

62.593 (matching shares)

£16.18

36.169 (matching shares)

£16.18

85.292 (matching shares)

£16.18

62.582 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

736.194

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

170.501 (personal contribution)

£16.18

201.553 (personal contribution)

£16.18

173.006 personal contribution)

£16.18

201.553 (personal contribution)

£16.18

172.994 (personal contribution)

£16.18

170.501 (matching shares)

£16.18

201.553 (matching shares)

£16.18

173.006 (matching shares)

£16.18

201.553 (matching shares)

£16.18

172.994 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,839.214

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$42.50

70.929 (personal contribution)

$42.50

70.929 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

141.858

$42.50

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

57.960 (personal contribution)

£16.18

108.550 (personal contribution)

£16.18

78.775 (personal contribution)

£16.18

57.960 (personal contribution)

£16.18

108.550 (personal contribution)

£16.18

78.763 (personal contribution)

£16.18

57.960 (matching shares)

£16.18

108.550 (matching shares)

£16.18

78.775 (matching shares)

£16.18

57.960 (matching shares)

£16.18

108.550 (matching shares)

£16.18

78.763 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

981.116

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

78.015 (personal contribution)

£16.18

158.805 (personal contribution)

£16.18

118.568 (personal contribution)

£16.18

78.002 (personal contribution)

£16.18

158.805 (personal contribution)

£16.18

118.568 (personal contribution)

£16.18

78.015 (matching shares)

£16.18

158.805 (matching shares)

£16.18

118.568 (matching shares)

£16.18

78.002 (matching shares)

£16.18

158.805 (matching shares)

£16.18

118.568 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,421.526

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

52.988 (personal contribution)

£16.18

97.162 (personal contribution)

£16.18

74.644 (personal contribution)

£16.18

52.988 (matching shares)

£16.18

97.162 (matching shares)

£16.18

74.644 matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

449.588

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$42.50

40.363 (personal contribution)

$42.50

90.880 (personal contribution)

$42.50

75.270 (personal contribution)

$42.50

40.363 (personal contribution)

$42.50

90.880 (personal contribution)

$42.50

75.258 (personal contribution)

$42.50

40.363 (matching shares)

$42.50

90.880  (matching shares)

$42.50

75.270  (matching shares)

$42.50

40.363  (matching shares)

$42.50

90.880  (matching shares)

$42.50

75.258 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

826.028

$42.50

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.18

114.838 (personal contribution)

£16.18

186.805 (personal contribution)

£16.18

128.784 (personal contribution)

£16.18

114.838 (personal contribution)

£16.18

186.805 (personal contribution)

£16.18

128.784 (personal contribution)

£16.18

114.838 (matching shares)

£16.18

186.805 (matching shares)

£16.18

128.784 (matching shares)

£16.18

114.838 (matching shares)

£16.18

186.805 (matching shares)

£16.18

128.784 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,721.708

£16.18

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEDLFFDDFXBBE

a d v e r t i s e m e n t